Publication Month: Dec 2021 | Report Code: TIPRE00003539 | No. of Pages: 181 | Category: Pharmaceuticals | Status: Published
Veterinary vaccines are parenteral products used to prevent infectious diseases caused by various pathogens. These vaccines protect animals from a variety of life-threatening diseases. Veterinary vaccines serve a critical role in ensuring the longevity, good health, and overall production of pets and livestock cost-effectively. The veterinary vaccines are classified as inactivated, live-attenuated, toxoid, and recombinant vaccines. Key factors driving the market's growth are the increasing incidence of zoonotic diseases and the rising prevalence of foodborne diseases and infections. However, strict government rules related to the usage of veterinary vaccines are hampering the market growth. The veterinary vaccines market, by region, is segmented into North America, Europe, Asia Pacific (APAC), the Middle East and Africa (MEA), and South and Central America (SAM). North America dominates the global market due to increased adoption of companion animals, increased consumption of meat and milk, and increased understanding of the benefits of animal immunizations.
|Market Size Value in||US$ 9,984.65 million in 2021|
|Market Size Value by||US$ 15,536.38 million by 2028|
|Growth rate||CAGR of 6.5% from 2021 to 2028|
|No. of Pages||181|
|No. of Tables||111|
|No. of Charts & Figures||76|
|Historical data available||Yes|
|Segments covered||Vaccine Type and Technology|
|Regional scope||North America, Europe, Asia Pacific, Middle East & Africa, South & Central America|
|Country scope||US, Canada, Mexico, UK, Germany, Spain, Italy, France, India, China, Japan, South Korea, Australia, UAE, Saudi Arabia, South Africa, Brazil, Argentina|
|Report coverage||Revenue forecast, company ranking, competitive landscape, growth factors, and trends|
|Free Sample Copy Available|
Animals carry hazardous bacteria, viruses, parasites, and fungi to people, resulting in illness. Such diseases are known as zoonotic diseases or zoonoses. The clinical effect of zoonotic illnesses may range from mild to severe and sometimes lead to death. Zoonotic illnesses are ubiquitous in the world. As per the Center for Disease Control (CDC) projections, >6 out of every 10 existing infectious diseases in people can spread through animals, and 3 out of every 4 new or future infectious diseases in people will come from animals. Moreover, in 2016, at least 55,000 individuals perished of rabies in Asia and Africa.
In the past decades, several new infectious human diseases causing viruses, such as Ebola virus, West Nile virus, Human Immunodeficiency Virus (HIV), Nipah virus, and Hantavirus infections, have evolved from animal reservoirs. Outbreaks, such as severe acute respiratory syndrome (SARS) and avian influenza, have underlined the potential of germs from animal reservoirs to adapt to human hosts. More than three-quarters of the human diseases that are new, emerging, or re-emerging at the beginning of the 21st century are caused by pathogens derived from animals or products of animal origin. According to the WHO, ~60% of new infectious diseases identified globally are zoonoses, and every year, over 1 billion cases of illness and millions of deaths occur from zoonoses. Over 30 novel human infections have been found in the previous three decades, and 75% of these are originated from animals. Hence, the emerging and re-emerging zoonotic illnesses propel the demand for animal health. Thus, companies produce improved medications and vaccines to aid animal owners or other stakeholders to maintain the overall health of animals. Therefore, the growth in the incidence of zoonotic diseases boosts the veterinary vaccines market growth.
The global veterinary vaccines market, based on vaccine type, is segmented into livestock vaccines, companion animal vaccines, and others. The livestock vaccines segment is likely to hold the largest market share in 2021. However, the companion animal segment is anticipated to register the highest CAGR of 7.0% during the forecast period.
The global veterinary vaccines market, based on technology, is segmented into live attenuated vaccines, inactivated vaccines, toxoid vaccines, recombinant vaccines, conjugate vaccines, and others. In 2021, the live attenuated vaccines segment is likely to hold the largest market share. However, the inactivated vaccines segment is expected to grow at the highest CAGR from 2021 to 2028.
The veterinary vaccines market players adopt organic strategies, such as product launch and expansion, to expand their footprint and product portfolio worldwide and to meet the growing demand.
Geographically, the veterinary vaccines market is segmented into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and the Rest of APAC), the Middle East & Africa (Saudi Arabia, the UAE, South Africa, and the Rest of MEA), and South and Central America (Brazil, Argentina, and the Rest of SCAM).
The countries in Europe are highly affected due to the COVID-19 pandemic. To control the outbreak of virus various restrictions were imposed by the government. This led to disruption, limitation, challenges, and changes in each sector of every industry. Likewise, animal vaccines industry was also impacted by the pandemic. For instance, veterinary organizations overseas have recommended limiting animal patient care to acutely ill animals and emergencies. Furthermore, the lockdowns have led to rescheduling of annual checkup exams and elective vaccination procedures.
However, various key players have ensured the supply of animal vaccines as the governmental institutions across the globe are taking strict measures to maintain the supply to avoid zoonotic viruses from spreading into communities. However, the overall impact of COVID-19 on the animal vaccines market remains fairly negative, owing to fall in demand as veterinary visits are limited, and animal healthcare approach is changed to providing care to emergency cases and critically ill animals.